Navigation Links
Phase 1 Study Initiated with Micromet Anti-GM-CS Human Antibody MT203
Date:6/18/2009

oduct development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal antibodies. BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's immune system to eliminate cancer cells. Five of Micromet's antibodies are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in a phase 1 clinical trial for the treatment of patients with solid tumors. MT110 binds to the epithelial cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after complete resection of liver metastases, and a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet's monoclonal antibody MT293, also known as TRC093, is licensed to TRACON Pharmaceuticals, Inc., and is in a phase 1 clinical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis, is in a phase 1 clinical trial conducted by Micromet's collaboration partner Nycomed. Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai, is also expected to initiate a first phase 1 clinical trial with Micromet's glycolipid-binding human antibody MT228 for the treatment of melanoma.

Microme
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. ORNL finding could help electronics industry enter new phase
2. Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study
3. FluoroPharma to Present Phase I Study Results of Novel Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) Tracer
4. InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting
5. Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia
6. Medifocus, Inc. receives Authorization Approval from Health Canada to launch its pivotal Phase III clinical study of focused microwave heating for treatment of breast cancer in Canada
7. Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study
8. Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack
9. Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
10. Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
11. Hyperion Therapeutics Announces Results of Phase I Study in Patients With Liver Cirrhosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... children with complex chronic illnesses can receive effective, less expensive ... with easy access to a team of dedicated health care ... to become seriously ill and need either hospitalization or a ... an enhanced medical home clinic at the University of Texas ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 (HealthDay ... of youth" drug that can delay the effects of aging ... suggests. Seniors received a significant boost to their immune ... pathway linked to aging and immune function, researchers with the ... a version of the drug rapamycin, improved the seniors, immune ...
(Date:12/25/2014)... Viejo, California (PRWEB) December 25, 2014 ... release of ProFire 5k. A fully customizable business presentation ... . , “Adding the ProFire 5k business tool, users ... Said Christina Austin, CEO of Pixel Film Studios. “ProFire ... look and style to add professionalism to a presentation” ...
(Date:12/24/2014)... December 25, 2014 AlignLife of Wauwatosa ... to afford certain items. During the holiday season, AlignLife looks ... over 70 toys," says Dr. Sara Mahalko-Leonhardt, owner of AlignLife. ... such joy, knowing that we are able to give kids ... it not been for the generosity of our patients." , ...
(Date:12/24/2014)... 25, 2014 Recently, iFitDress.com, a famous dress ... prom dresses under $150 . All these items are brand ... website has already been updated with the new range of ... ordered so far. All iFitDress.com’s designs are made according to ... using great materials. Every outfit from the company is handpicked ...
Breaking Medicine News(10 mins):Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Many Prom Dresses under 150 from Well-known Dress Manufacturer iFitDress.com 2
... to Fund Growth, IRVINE, Calif., Sept. 17 ... announced that it has retained,investment banking firm Empire ... and,lead financing strategies. Assured Pharmacy, Inc. is a ... pain and other,long-term care conditions. "Empire Financial ...
... Symmetry Medical Inc.,(NYSE: SMA ), an independent ... and other medical markets, announced today the launch ... which contains improved,user- friendly features. The ... easy to,find product information and a streamlined log-in ...
... might improve treatment, researchers say , , MONDAY, Sept. 17 ... gene that plays a crucial role in the ability ... The finding that transcription factor AP2C (TFAP2C) controls multiple ... for hormone-responsive breast cancer and may help explain differences ...
... In October the American College of Physicians (ACP) will ... Dr. Harvey Makadon, Dr. Ken Mayer, and Hilary Goldhammer ... Dr. Jennifer Potter of Beth Israel Deaconess Medical Center, ... medical providers about the unique health care needs of ...
... of Warrenton, Virginia announces an innovative twist to ... too familiar with,traveling to food shows where vendors ... winning a sale. Vernon Rhea, Director of Nutrition,and ... long-standing,commitment to individualized patient care to the selection ...
... Debate, WASHINGTON, Sept. 17 The British ... partner,with three Los Angeles area universities to present ... of the National Theatre of Scotland,s,Black Watch, the ... as described by soldiers in Scotland,s legendary Black ...
Cached Medicine News:Health News:Assured Pharmacy Retains Empire Financial Group 2Health News:Assured Pharmacy Retains Empire Financial Group 3Health News:Symmetry Medical Launches New Global Web site 2Health News:Symmetry Medical Launches New Global Web site 3Health News:American College of Physicians publishes 'The Fenway Guide to LGBT Health' 2Health News:Fauquier Health System Holds a Food Show with a Twist Long Term Care Patients Hold the Judge's Pen as Vendors Vie for Approval 2Health News:British Council and Los Angeles Area Universities Partner to Host Transatlantic Dialogues 2Health News:British Council and Los Angeles Area Universities Partner to Host Transatlantic Dialogues 3Health News:British Council and Los Angeles Area Universities Partner to Host Transatlantic Dialogues 4Health News:British Council and Los Angeles Area Universities Partner to Host Transatlantic Dialogues 5
(Date:12/24/2014)... and FARMINGTON, Conn. ... Inc. (NYSE MKT: PTN), a biopharmaceutical company developing ... diseases with significant unmet medical need and commercial ... a private placement of 2,050,000 shares of its ... 24,949,325 shares of its common stock.  Funds under ...
(Date:12/24/2014)... 2014  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), ... the development of brachytherapy devices and medical isotopes ... it has filed a de novo ... for marketing clearance for its patented Y-90 RadioGel(TM) ... Food, Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... 23, 2014   Assurex Health, a personalized ... healthcare providers for behavioral health and chronic pain ... million in equity financing from new and existing ... President and Chief Executive Officer. The ... of Assurex Health,s GeneSight ®  products.  ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today a ... Phase 3 study required for New Drug Application (NDA) ... 140 patients has greater than 90% power to detect ... to enrol additional patients. QRxPharma anticipates completing analysis of ...
... or "Company") (Nasdaq: UNIS, ASX: UNS), today announced that ... clearance from the U.S. Food and Drug Administration (FDA). ... variant of the Unitract™ 1mL Insulin Syringe for which ... syringes which are primarily used by people with diabetes, ...
Cached Medicine Technology:QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuo®IR 2QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuo®IR 3Unilife Corporation Secures FDA 510k Clearance for the Unitract™ 1mL Tuberculin Syringe 2Unilife Corporation Secures FDA 510k Clearance for the Unitract™ 1mL Tuberculin Syringe 3
The INRatio meter is a diagnostic Point Of Care system that provides Prothrombin Time (PT) and International Normalized Ratio (INR) results using one drop of fresh capillary whole blood from a finger...
... The ADC drugs of abuse tests are highly ... the SAMHSA recommended cut-off as confirmed by GC/MS ... A more specific alternative method (such as GC/MS) ... confirmed result. Professional judgment should be applied to ...
Ovulation test for the rapid detection of LH in urine. Our ovulation tests, designed to accurately detect fertility in a user-friendly presentation, are also available for professional and over-the-c...
... designed for women actively wishing to become pregnant. ... the time of high fertility typically up ... her peak fertility. By doing so, it maximises ... number of test sticks and a hand held ...
Medicine Products: